Unknown PHASE2 INTERVENTIONAL NCT00445159

UT-15C SR in the Treatment of Critical Limb Ischemia

An Investigator Initiated Eight Week Two Center Open-Label Pilot Study of the Tolerability and Safety of Oral UT-15C (Treprostinil Diethanolamine)SR Tablets in Patients With Critical Limb Ischemia (CLI) and Ischemic Rest Pain

Sponsor: Southern Arizona Vascular Institute

Conditions Critical Limb Ischemia

Interventions UT-15C SR (treprostinil diethanolamine) 1mg oral tablets

Updated 4 times since 2017 Last updated: Mar 7, 2007 Started: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Critical Limb Ischemia, this trial is ongoing. The trial is conducted by Southern Arizona Vascular Institute and has accumulated 4 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE2

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Southern Arizona Vascular Institute
Southern Illinois University

Data source: Southern Arizona Vascular Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Springfield, United States
• Tucson, United States